• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026.

    Key Financial and Operating Results

     

    Q4 2025

     

    Q4 2024

     

    FY 2025

     

    FY 2024

    Net sales

    $226.2

     

    $213.6

     

    $925.3

     

    $854.5

    Net (loss) earnings*

    $-1.8

     

    $4.5

     

    $10.8

     

    $42.0

    Diluted EPS

    $-0.10

     

    $0.23

     

    $0.58

     

    $2.19

    Adjusted diluted EPS(1)

    $0.60

     

    $0.64

     

    $1.93

     

    $2.59

    Adjusted EBITDA(2)

    $27.3

     

    $25.5

     

    $101.3

     

    $110.3

    USANA Active Customers

    387,000

     

    454,000

     

    387,000

     

    454,000

    Hiya Active Monthly Subscribers

    181,700

     

    N/A

     

    181,700

     

    N/A

    *Pretax earnings for Q4 2025 totaled $4.0 million with income tax expense of $5.8 million. The adjustment to income taxes during the period, largely as a result of one-time impairment and cost realignment charges, is about $3.1 million greater than what would have been expected using the previously expected 65% tax rate.

    Net sales, Net (loss) earnings and Adjusted EBITDA figures in millions.

    Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.

    Fiscal Year 2026 Outlook

    • Consolidated net sales between $925 million and $1.0 billion, or flat to 8% growth.
    • Net earnings between $20.3 million and $26.6 million.
    • Diluted EPS between $1.11 and $1.45.
    • Adjusted Diluted EPS(1) between $1.95 and $2.29.
    • Adjusted EBITDA(2) between $101.3 million and $109.3 million.

    Q4 2025 Financial Performance

    Consolidated Results

     

    Year-Over-Year

    Sequentially

    Net sales

    $226 million

    +6% *

    +6% *

    Net (loss)

    -$1.8 million

    N/A

    N/A

    Diluted EPS

    -$0.10

    N/A

    N/A

    Adjusted diluted EPS(1)

    $0.60

    -6%

    N/A

    Adjusted EBITDA(2)

    $27.0 million

    +7%

    +98%

    *No meaningful FX impact

    Net (loss) earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.

    "USANA delivered fourth quarter net sales in line with our preliminary results announced on January 12, 2026," said Kevin Guest, Chairman and Chief Executive Officer. "We began to see signs of stabilization in active customer counts in our core nutritional business as net sales in this segment increased modestly sequentially, led by growth in key markets including mainland China, the United States and Canada. Meanwhile, our omnichannel brands, Hiya and Rise, posted solid year-over-year growth."

    Fiscal Year 2025 Financial Performance

    Consolidated Results

    Net sales

    $925 million

    +8% YOY

     

     

    +9% constant currency

     

     

    -$3 million YOY FX impact

    Net earnings

    $10.8 million

    -74%

    Diluted EPS

    $0.58

    -74%

    Adjusted diluted EPS(1)

    $1.93

    -25%

    Adjusted EBITDA(2)

    $101.3 million

    -8%

    Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA

    Mr. Guest continued, "Fiscal 2025 net sales grew 8%, driven primarily by a full-year contribution from Hiya. Net sales in the core nutritional business declined 8%, reflecting a challenging environment for customer acquisition in key markets. Despite this challenge, we continued to execute our diversification strategy towards an omnichannel model. That strategy is designed to support growth beyond our core nutritional business as well as to restructure and modernize our business for today's evolving marketplace. Rise Wellness generated strong momentum with sales tripling, albeit off a small base in 2024, as distribution expanded into key retail outlets. The business is on pace for a robust year of sales growth supported by the launch of Protein Pop at a large club retailer in the first quarter. Net sales outside of our core nutritional business represented 16% of consolidated net sales in 2025, up from approximately 1% in 2024. We expect this share to increase to more than 20% of consolidated net sales in fiscal 2026."

    Q4 2025 Core Nutritional Business Regional Results:

    Asia Pacific Region

     

     

    Year-Over-Year

    Year-over-Year (Constant Currency)

    Sequentially

    Net sales

    $151 million

    -10%

    No material FX impact

    +8%

    USANA Active Customers

    306,000

    -15%

    N/A

    -1%

    Asia Pacific Sub-Regions

     

     

     

    Year-Over-Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Greater China

    Net sales

    $100 million

    -11%

    No material FX impact

    +8%

    USANA Active

    208,000

    -15%

    N/A

    -1%

    Customers

    North Asia

    Net sales

    $17 million

    +2%

    +5%

    -5%

    USANA Active

    35,000

    -8%

    N/A

    -5%

    Customers

    Southeast Asia Pacific

    Net sales

    $34 million

    -10%

    -12%

    +17%

    USANA Active

    63,000

    -18%

    N/A

    +3%

    Customers

    Americas and Europe Region

     

     

    Year-Over-Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Net sales*

    $45 million

    +1%

    Flat

    +4%

    USANA Active Customers

    81,000

    -13%

    N/A

    +1%

    *Includes $4.5 million of ‘Other'

    Q4 2025 Hiya Direct to Consumer Results:

    Hiya

    Net sales

    $30 million

    Active Monthly Subscribers

    181,700

    Balance Sheet

    The Company ended the year with $158 million in cash and cash equivalents and $14 million of debt. As of January 3, 2026, inventory totaled $107 million, an increase of approximately $35 million, or 48% compared to balances at year-end 2024. This increase was primarily driven by the addition of inventory to support the rapid growth of the Rise Wellness brands and a planned ramp up of raw materials inventory as part of bringing the production of Hiya products in-house. Importantly, our balance sheet remains in a strong net cash position, providing us with the financial flexibility to continue executing our strategic priorities.

    The Company repurchased 927,000 shares in fiscal 2025 for an investment of $28 million. As of January 3, 2026, the Company had approximately $34 million remaining under the current share repurchase authorization.

    Fiscal Year 2026 Outlook

    Mr. Guest continued, "We are leveraging our strong foundation in the nutrition business and expanding beyond our legacy channel to connect with a greater number of health-conscious consumers worldwide. We see an extraordinary opportunity in a growing global health and wellness market to strengthen our brand relevance through an omnichannel approach. By deepening consumer engagement, empowering our Brand Partners, and executing with discipline, we believe we can accelerate profitable growth, extend our competitive advantages, and deliver sustainable long-term value for our shareholders.

    "We also remain focused on product innovation and development to meet the evolving nutritional needs of our consumers. We introduced several new products and upgraded several top-selling products in 2025, and plan to launch these products across all markets in 2026. Furthermore, we intend to accelerate our technology initiatives to modernize our core systems and fundamentally improve how customers experience our brand while driving future cost efficiencies across our IT infrastructure. We are planning to strategically leverage best-in-class third-party platforms to move faster, scale smarter, and deliver capabilities to enable future growth and improve customer interactions. Our focus is on deploying the most effective technologies and partnering with industry-leading providers to create real value for customers and a durable advantage for our business. As I have recently resumed the CEO role, this plan is still being finalized and is not reflected in our fiscal 2026 guidance, and we will provide an update upon its full formalization and approval.

    "Hiya is expected to deliver solid top line growth in 2026, driven by continued strength in its core direct-to-consumer business and early expansion into new distribution channels and international markets. Moreover, we have begun manufacturing Hiya products in‑house, a strategic shift that we expect will generate savings in the back half of 2026 as efficiencies scale and integration benefits materialize.

    "Building on the strong momentum over the last several quarters, Rise Wellness is expected to accelerate net sales growth in 2026. Notably, Rise Wellness consists of two brands, Rise Bar and Protein Pop – a new product line we launched mid-year 2025. While Rise Bar sales were driven by entrance into a large club retailer in 2025, Protein Pop went from concept to launch on the shelves of a key retailer over a few short months. Much of the growth in Rise Wellness is expected to be driven by expansion of Protein Pop into the club retail channel."

    The Company is providing its outlook for fiscal year 2026, as detailed in the table below:

    Fiscal Year 2026 Outlook

     

    Range

    Core nutritional business net sales

    $720 to $765 million*

    Hiya net sales

    $140 to $155 million

    Rise Wellness net sales

    $65 to $80 million

    Consolidated net sales

    $925 million to $1.0 billion

     

     

    Net earnings

    $20.3 million to $26.6 million

    Diluted EPS

    $1.11 to $1.45

    Adjusted diluted EPS(1)

    $1.95 to $2.29

    Adjusted EBITDA(2)

    $101.3 million to $109.3 million

    *Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.

    Doug Hekking, Chief Financial Officer, said, "Fourth‑quarter and full‑year net sales came in modestly ahead of our expectations, although reported GAAP results reflected the impact of two notable items. During the quarter, we recorded a non‑cash impairment charge of $7.0 million of goodwill and intangibles in one of our reporting units, that resulted from a sustained decline in our share price and resulting market capitalization. We also incurred a $6.5 million charge related to our previously communicated cost realignment initiatives, primarily aligning headcount with sales levels. As a result of the impact of the impairment and cost realignment initiatives, the annualized effective income tax rate in the fourth quarter increased from 65.0% to 72.4%. The adjustment was approximately $3.1 million greater than what would have been expected using the previously expected 65.0% tax rate. The fourth quarter also included incremental net sales of approximately $11.2 million attributable to the additional week of operations in the core nutritional business.

    "Looking ahead, we are projecting fiscal 2026 consolidated net sales in a range of flat to 8% growth. Our outlook for the core nutritional business anticipates an approximately 0-5% decline in fiscal 2026, but we remain confident that the actions underway will stabilize the business over time and ultimately position it to return to sustainable growth. Hiya is anticipated to grow net sales 6% to 17%, while Rise Wellness is expected to continue to deliver accelerated net sales growth.

    "We are making meaningful investments in inventory, working capital, and capital expenditures, while simultaneously deploying incremental operational resources to support the growth of Hiya and Rise Wellness including building brand awareness. These actions are designed to strengthen the scalability of both platforms and position the brands for sustained, long-term value creation."

    ____________________

    (1)

     

    Adjusted Diluted EPS is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted EPS. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted EPS (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    (2)

     

    Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    Non-GAAP Financial Measures

    This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

    Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

    Adjusted diluted EPS (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.

    Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted EPS (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted EPS. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

    Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP)

    (in thousands)

     

     

     

    Quarter Ended

     

    Year Ended

     

     

    January 3,

    2026

     

    December 28,

    2024

     

    January 3,

    2026

     

    December 28,

    2024

    Net (loss) earnings attributable to USANA (GAAP)

     

    $

    (1,775

    )

     

    $

    4,454

     

     

    $

    10,760

     

     

    $

    42,030

     

    Net earnings attributable to noncontrolling interest

     

     

    180

     

     

     

    30

     

     

     

    717

     

     

     

    30

     

    Net (loss) earnings

     

    $

    (1,595

    )

     

    $

    4,484

     

     

    $

    11,477

     

     

    $

    42,060

     

     

     

     

     

     

     

     

     

     

    Adjustments:

     

     

     

     

     

     

     

     

    Income taxes

     

    $

    5,772

     

     

    $

    5,945

     

     

    $

    30,050

     

     

    $

    34,291

     

    Interest (income) expense

     

     

    (372

    )

     

     

    (2,609

    )

     

     

    (1,573

    )

     

     

    (11,038

    )

    Depreciation and amortization

     

     

    5,488

     

     

     

    5,590

     

     

     

    21,538

     

     

     

    21,935

     

    Amortization of intangible assets - Hiya

     

     

    4,798

     

     

     

    294

     

     

     

    18,164

     

     

     

    294

     

    Earnings before interest, taxes, depreciation, and amortization (EBITDA)

     

    $

    14,091

     

     

    $

    13,704

     

     

    $

    79,656

     

     

    $

    87,542

     

     

     

     

     

     

     

     

     

     

    Add EBITDA adjustments:

     

     

     

     

     

     

     

     

    Non-cash share-based compensation

     

     

    3,750

     

     

     

    3,613

     

     

     

    13,828

     

     

     

    14,558

     

    Transaction, integration and transition costs - Hiya

     

     

    443

     

     

     

    8,243

     

     

     

    1,314

     

     

     

    8,243

     

    Inventory step-up - Hiya

     

     

    —

     

     

     

    38

     

     

     

    1,126

     

     

     

    38

     

    Cost realignment

     

     

    6,463

     

     

     

    —

     

     

     

    6,463

     

     

     

    —

     

    Impairment

     

     

    6,967

     

     

     

    —

     

     

     

    6,967

     

     

     

    —

     

    Gain on disposal of assets

     

     

    (3,240

    )

     

     

    —

     

     

     

    (3,240

    )

     

     

    —

     

    Consolidated adjusted EBITDA

     

     

    28,474

     

     

     

    25,598

     

     

     

    106,114

     

     

     

    110,381

     

    Less: Adjusted EBITDA attributable to noncontrolling interest

     

     

    (1,195

    )

     

     

    (101

    )

     

     

    (4,799

    )

     

     

    (101

    )

    Adjusted EBITDA attributable to USANA

     

    $

    27,279

     

     

    $

    25,497

     

     

    $

    101,315

     

     

    $

    110,280

     

    Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)

    (in thousands, except per share data)

     

     

     

    Quarter Ended

     

    Year Ended

     

     

    January 3,

    2026

     

    December 28,

    2024

     

    January 3,

    2026

     

    December 28,

    2024

    Net (loss) earnings attributable to USANA (GAAP)

     

    $

    (1,775

    )

     

    $

    4,454

     

     

    $

    10,760

     

     

    $

    42,030

     

     

     

     

     

     

     

     

     

     

    (Loss) earnings per common share - Diluted (GAAP)

     

    $

    (0.10

    )

     

    $

    0.23

     

     

    $

    0.58

     

     

    $

    2.19

     

    Weighted Average common shares outstanding - Diluted

     

     

    18,302

     

     

     

    19,104

     

     

     

    18,574

     

     

     

    19,162

     

     

     

     

     

     

     

     

     

     

    Adjustment to net (loss) earnings:

     

     

     

     

     

     

     

     

    Transaction, integration and transition costs - Hiya

     

    $

    443

     

     

    $

    8,243

     

     

    $

    1,314

     

     

    $

    8,243

     

    Inventory step-up - Hiya

     

     

    —

     

     

     

    38

     

     

     

    1,126

     

     

     

    38

     

    Cost realignment

     

     

    6,463

     

     

     

    —

     

     

     

    6,463

     

     

     

    —

     

    Impairment

     

     

    6,967

     

     

     

    —

     

     

     

    6,967

     

     

     

    —

     

    Gain on disposal of assets

     

     

    (3,240

    )

     

     

    —

     

     

     

    (3,240

    )

     

     

    —

     

    Amortization of intangible assets - Hiya

     

     

    4,798

     

     

     

    294

     

     

     

    18,164

     

     

     

    294

     

    Adjustments to net (loss) earnings attributable to noncontrolling interest

     

     

    (1,015

    )

     

     

    (70

    )

     

     

    (4,081

    )

     

     

    (70

    )

    Income tax effect of adjustments to net earnings (loss)

     

     

    (1,658

    )

     

     

    (823

    )

     

     

    (1,662

    )

     

     

    (823

    )

    Adjusted net earnings attributable to USANA

     

    $

    10,983

     

     

    $

    12,136

     

     

    $

    35,811

     

     

    $

    49,712

     

     

     

     

     

     

     

     

     

     

    Adjusted earnings per common share - Diluted

     

    $

    0.60

     

     

    $

    0.64

     

     

    $

    1.93

     

     

    $

    2.59

     

    Weighted average common shares outstanding - Diluted

     

     

    18,302

     

     

     

    19,104

     

     

     

    18,574

     

     

     

    19,162

     

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, February 18, 2026 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2026 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to Hiya's ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Rise Wellness' dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt the Company's overall strategic plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability to retain key personnel of Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com. More information on Rise Wellness can be found on www.risebar.com.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

     

     

     

    Quarter Ended

     

    Year Ended

     

     

    January 3,

    2026

     

    December 28,

    2024

     

    January 3,

    2026

     

    December 28,

    2024

    Net sales

     

    $

    226,200

     

     

    $

    213,613

     

     

    $

    925,257

     

     

    $

    854,503

     

    Cost of sales

     

     

    49,408

     

     

     

    38,553

     

     

     

    200,852

     

     

     

    161,212

     

    Gross profit

     

     

    176,792

     

     

     

    175,060

     

     

     

    724,405

     

     

     

    693,291

     

    Operating expenses:

     

     

     

     

     

     

     

     

    Brand Partner incentives

     

     

    81,462

     

     

     

    93,502

     

     

     

    336,171

     

     

     

    363,699

     

    Selling, general and administrative

     

     

    78,081

     

     

     

    73,348

     

     

     

    337,372

     

     

     

    263,268

     

    Cost realignment and impairment

     

     

    13,430

     

     

     

    —

     

     

     

    13,430

     

     

     

    —

     

    Total operating expenses

     

     

    172,973

     

     

     

    166,850

     

     

     

    686,973

     

     

     

    626,967

     

    Earnings from operations

     

     

    3,819

     

     

     

    8,210

     

     

     

    37,432

     

     

     

    66,324

     

    Other income (expense):

     

     

     

     

     

     

     

     

    Interest income

     

     

    495

     

     

     

    2,738

     

     

     

    2,415

     

     

     

    11,319

     

    Interest expense

     

     

    (123

    )

     

     

    (129

    )

     

     

    (842

    )

     

     

    (281

    )

    Other, net

     

     

    (14

    )

     

     

    (390

    )

     

     

    2,522

     

     

     

    (1,011

    )

    Other income (expense), net

     

     

    358

     

     

     

    2,219

     

     

     

    4,095

     

     

     

    10,027

     

    Earnings before income taxes

     

     

    4,177

     

     

     

    10,429

     

     

     

    41,527

     

     

     

    76,351

     

    Income taxes

     

     

    5,772

     

     

     

    5,945

     

     

     

    30,050

     

     

     

    34,291

     

    Net (loss) earnings

     

     

    (1,595

    )

     

     

    4,484

     

     

     

    11,477

     

     

     

    42,060

     

    Less: Net (loss) earnings attributable to redeemable noncontrolling interest

     

     

    (180

    )

     

     

    (30

    )

     

     

    (717

    )

     

     

    (30

    )

    Net (loss) earnings attributable to USANA

     

    $

    (1,775

    )

     

    $

    4,454

     

     

    $

    10,760

     

     

    $

    42,030

     

     

     

     

     

     

     

     

     

     

    (Loss) earnings per common share attributable to USANA

     

     

     

     

     

     

     

     

    (Loss) earnings per share - diluted

     

    $

    (0.10

    )

     

    $

    0.23

     

     

    $

    0.58

     

     

    $

    2.19

     

    Weighted average shares outstanding - diluted

     

     

    18,302

     

     

     

    19,104

     

     

     

    18,574

     

     

     

    19,162

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    January 3,

    2026

     

    As of

    December 28,

    2024

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    158,380

     

    $

    181,768

    Inventories

     

    102,608

     

     

    69,735

    Prepaid expenses and other current assets

     

    27,417

     

     

    27,684

    Total current assets

     

    288,405

     

     

    279,187

    Property and equipment, net

     

    94,383

     

     

    94,565

    Goodwill

     

    137,962

     

     

    144,168

    Intangible assets, net

     

    133,151

     

     

    151,823

    Deferred tax assets

     

    27,209

     

     

    19,644

    Other assets*

     

    61,805

     

     

    58,806

    Total assets

    $

    742,915

     

    $

    748,193

    LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    17,263

     

    $

    11,984

    Line of credit

     

    14,000

     

     

    23,000

    Other current liabilities

     

    97,302

     

     

    104,641

    Total current liabilities

     

    128,565

     

     

    139,625

    Deferred tax liabilities

     

    4,892

     

     

    4,073

    Other long-term liabilities

     

    23,186

     

     

    18,163

    Total liabilities

     

    156,643

     

     

    161,861

     

     

     

     

    Redeemable noncontrolling interest

     

    53,168

     

     

    54,223

     

     

     

     

    Total stockholders' equity attributable to USANA

     

    533,104

     

     

    532,109

    Total liabilities, redeemable noncontrolling interest, and stockholders' equity

    $

    742,915

     

    $

    748,193

    *Includes noncurrent inventories of $4,799 and $2,688 as of 03-Jan-26 and 28-Dec-24, respectively. Total inventories were $107,407 and $72,423 as of 03-Jan-26 and 28-Dec-24, respectively.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter Ended

     

     

     

     

     

     

     

     

     

    January 3,

    2026

     

    December 28,

    2024

     

    Change

    from

    prior

    year

     

    Percent

    change

     

    Currency

    impact

    on

    sales

     

    Percent

    change

    excluding

    currency

    impact

    Core nutritional:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Greater China

    $

    100,053

     

    44.2

    %

     

    $

    112,587

     

    52.7

    %

     

    $

    (12,534

    )

     

    (11.1

    )%

     

    $

    1,332

     

     

    (12.3

    )%

    Southeast Asia Pacific

     

    34,211

     

    15.1

    %

     

     

    38,061

     

    17.8

    %

     

     

    (3,850

    )

     

    (10.1

    )%

     

     

    592

     

     

    (11.7

    )%

    North Asia

     

    16,830

     

    7.5

    %

     

     

    16,542

     

    7.8

    %

     

     

    288

     

     

    1.7

    %

     

     

    (614

    )

     

    5.5

    %

    Asia Pacific total

     

    151,094

     

    66.8

    %

     

     

    167,190

     

    78.3

    %

     

     

    (16,096

    )

     

    (9.6

    )%

     

     

    1,310

     

     

    (10.4

    )%

    Americas and Europe

     

    40,494

     

    17.9

    %

     

     

    42,776

     

    20.0

    %

     

     

    (2,282

    )

     

    (5.3

    )%

     

     

    619

     

     

    (6.8

    )%

    Core nutritional total

     

    191,588

     

    84.7

    %

     

     

    209,966

     

    98.3

    %

     

     

    (18,378

    )

     

    (8.8

    )%

     

     

    1,929

     

     

    (9.7

    )%

    Hiya(1)

     

    30,105

     

    13.3

    %

     

     

    1,970

     

    0.9

    %

     

     

    28,135

     

     

    N/A

     

     

     

    —

     

     

    N/A

     

    Other

     

    4,507

     

    2.0

    %

     

     

    1,677

     

    0.8

    %

     

     

    2,830

     

     

    168.8

    %

     

     

    —

     

     

    168.8

    %

    Consolidated total

    $

    226,200

     

    100.0

    %

     

    $

    213,613

     

    100.0

    %

     

    $

    12,587

     

     

    5.9

    %

     

    $

    1,929

     

     

    5.0

    %

    ______________________________

    (1) 

     

    Percentage change for Hiya is not applicable due to timing of the acquisition.

     USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CORE NUTRITIONAL BUSINESS ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

     

    Core Nutritional Business Active Brand Partners by Region(1)

     

     

    As of

    January 3, 2026

     

    As of

    December 28, 2024

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

     

    61,000

     

    35.1

    %

     

    67,000

     

    35.4

    %

    Southeast Asia Pacific

     

    46,000

     

    26.4

    %

     

    51,000

     

    27.0

    %

    North Asia

     

    27,000

     

    15.5

    %

     

    26,000

     

    13.8

    %

    Asia Pacific Total

     

    134,000

     

    77.0

    %

     

    144,000

     

    76.2

    %

     

     

     

     

     

     

     

     

     

    Americas and Europe

     

    40,000

     

    23.0

    %

     

    45,000

     

    23.8

    %

     

     

    174,000

     

    100.0

    %

     

    189,000

     

    100.0

    %

    Core Nutritional Business Active Preferred Customers by Region(2)

     

     

    As of

    January 3, 2026

     

    As of

    December 28, 2024

    Asia Pacific

     

     

     

     

     

     

     

     

    Greater China

     

    147,000

     

    69.0

    %

     

    179,000

     

    67.6

    %

    Southeast Asia Pacific

     

    17,000

     

    8.0

    %

     

    26,000

     

    9.8

    %

    North Asia

     

    8,000

     

    3.8

    %

     

    12,000

     

    4.5

    %

    Asia Pacific Total

     

    172,000

     

    80.8

    %

     

    217,000

     

    81.9

    %

     

     

     

     

     

     

     

     

     

    Americas and Europe

     

    41,000

     

    19.2

    %

     

    48,000

     

    18.1

    %

     

     

    213,000

     

    100.0

    %

     

    265,000

     

    100.0

    %

    ______________________________

    (1)

     

    Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2)

     

    Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    OPERATING RESULTS AS A PERCENTAGE OF NET SALES

    (unaudited)

     

     

     

    Quarter Ended

     

     

    January 3, 2026

     

    December 28, 2024

     

     

    Core

    nutritional &

    other

     

    Hiya direct-

    to-consumer

     

    Consolidated

     

    Core

    nutritional &

    other

     

    Hiya direct-

    to-consumer

     

    Consolidated

    Net sales

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

    Cost of sales

     

    20.6

    %

     

    29.9

    %

     

    21.8

    %

     

    17.9

    %

     

    30.4

    %

     

    18.0

    %

    Gross profit

     

    79.4

    %

     

    70.1

    %

     

    78.2

    %

     

    82.1

    %

     

    69.6

    %

     

    82.0

    %

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Brand Partner incentives

     

    41.5

    %

     

    —

    %

     

    36.0

    %

     

    44.2

    %

     

    —

    %

     

    43.8

    %

    Selling, general and administrative

     

    29.5

    %

     

    67.2

    %

     

    34.5

    %

     

    34.1

    %

     

    62.2

    %

     

    34.3

    %

    Cost realignment and impairment

     

    6.8

    %

     

    —

    %

     

    5.9

    %

     

    —

    %

     

    —

    %

     

    —

    %

    Total operating expenses

     

    77.8

    %

     

    67.2

    %

     

    76.4

    %

     

    78.3

    %

     

    62.2

    %

     

    78.1

    %

    Earnings from operations

     

    1.6

    %

     

    2.9

    %

     

    1.8

    %

     

    3.8

    %

     

    7.4

    %

     

    3.9

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    0.1

    %

     

    15.9

    %

     

    2.3

    %

     

    0.1

    %

     

    14.9

    %

     

    0.2

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Year Ended

     

     

    January 3, 2026

     

    December 28, 2024

     

     

    Core

    nutritional &

    other

     

    Hiya direct-

    to-consumer

     

    Consolidated

     

    Core

    nutritional &

    other

     

    Hiya direct-

    to-consumer

     

    Consolidated

    Net sales

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

     

    100.0

    %

    Cost of sales

     

    19.5

    %

     

    35.1

    %

     

    21.7

    %

     

    18.8

    %

     

    30.4

    %

     

    18.9

    %

    Gross profit

     

    80.5

    %

     

    64.9

    %

     

    78.3

    %

     

    81.2

    %

     

    69.6

    %

     

    81.1

    %

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Brand Partner incentives

     

    42.4

    %

     

    —

    %

     

    36.3

    %

     

    42.7

    %

     

    —

    %

     

    42.6

    %

    Selling, general and administrative

     

    32.2

    %

     

    62.3

    %

     

    36.5

    %

     

    30.7

    %

     

    62.2

    %

     

    30.8

    %

    Cost realignment and impairment

     

    1.7

    %

     

    —

    %

     

    1.5

    %

     

    —

    %

     

    —

    %

     

    —

    %

    Total operating expenses

     

    76.3

    %

     

    62.3

    %

     

    74.3

    %

     

    73.4

    %

     

    62.2

    %

     

    73.4

    %

    Earnings from operations

     

    4.2

    %

     

    2.6

    %

     

    4.0

    %

     

    7.8

    %

     

    7.4

    %

     

    7.7

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    0.2

    %

     

    13.8

    %

     

    2.1

    %

     

    0.1

    %

     

    14.9

    %

     

    0.2

    %

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260217081610/en/

    Investor contact:

    Andrew Masuda

    Investor Relations

    (801) 954-7201

    [email protected]

    Media contact:

    Sarah Searle

    (801) 954-7626

    [email protected]

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INFORMATION OFFICER Benedict Peter converted options into 2,788 shares and covered exercise/tax liability with 967 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:56:37 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF OPERATING OFFICER Noot Walter covered exercise/tax liability with 4,160 shares and converted options into 9,138 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:55:30 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF COMMERCIAL OFFICER Neidig Brent converted options into 7,310 shares and covered exercise/tax liability with 3,551 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    2/10/26 6:54:18 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    Amendment: USANA Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    2/11/26 4:51:10 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

    SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    1/21/26 1:21:12 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    1/12/26 6:29:11 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA's strategy, including the Company's initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 consolidated net sales of approximately $925 million, ahead of its most recently issued guidance of approximately $920 million. Initial Fiscal Year 2026 Net Sales Outlook The Company is issuing its initial net sales outlook for fi

    1/12/26 6:15:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3

    2/17/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Exec. Chairman/CEO Kevin Guest on Self-Renewal Day: Break Comfort Zones for Strategic Growth with Six Steps

    SALT LAKE CITY, Feb. 2, 2026 /PRNewswire/ -- As organizations face rapid market disruption and evolving leadership demands, Feb. 2 marks Self-Renewal Day, a pivotal time for business leaders to recalibrate strategies and personal development. "Growth does not happen by accident; it happens by choice," said  Kevin Guest, Executive Chairman & CEO at USANA Health Sciences (NYSE:USNA). "Self-Renewal Day is designed to prompt people to evaluate their lives, challenge complacency, and take deliberate steps toward personal and professional renewal." This annual observance is a critic

    2/2/26 7:05:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings

    ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Baystreet.ca News Commentary  VANCOUVER, BC, Jan. 19, 2026 /PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE:PM), Celsius Holdings (NASDAQ:CELH), USANA Health Sciences (NYSE:USNA), and Medifast (NYSE:MED

    1/19/26 12:10:00 PM ET
    $CELH
    $MED
    $PM
    Beverages (Production/Distribution)
    Consumer Staples
    Packaged Foods
    Medicinal Chemicals and Botanical Products